Edaravone

K K Jain MD (Dr. Jain is a consultant in neurology and has no relevant financial relationships to disclose.)
Originally released May 15, 2017; expires May 15, 2020

Historical note and terminology

Edaravone, a free radical scavenger, was approved in Japan for the treatment of cerebral infarction in 2005 and was available in South Korea as well. It was approved for the treatment of amyotrophic lateral sclerosis in those countries in 2015. Edaravone was approved by the U.S. Food and Drug Administration (FDA) in May 2017 and will be available in the United States in August 2017. This is the first approval of a new drug for amyotrophic lateral sclerosis since the approval of the only other drug for amyotrophic lateral sclerosis, riluzole, more than 2 decades ago. The drug will be sold under the brand name Radicava, and 1 year of treatment will cost more than $145,000. The manufacturer will provide some copay assistance to patients with commercial insurance and other help to those who are uninsured or face delays in coverage. Those who qualify might even be treated for free.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.